These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 1731500)

  • 21. [Chemotherapy in adenocarcinomas of the pancreas].
    Huguier M
    Gastroenterol Clin Biol; 2002 Nov; 26(11):1063; discussion 1063-4. PubMed ID: 12483149
    [No Abstract]   [Full Text] [Related]  

  • 22. Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.
    Alexander HR; Grem JL; Hamilton JM; Pass HI; Hong M; Fraker DL; Steinberg SM; McAtee N; Allegra BC; Johnston PG
    Cancer J Sci Am; 1995; 1(1):49-54. PubMed ID: 9166454
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma.
    Crown J; Casper ES; Botet J; Murray P; Kelsen DP
    J Clin Oncol; 1991 Sep; 9(9):1682-6. PubMed ID: 1875224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study.
    Zaanan A; Gauthier M; Malka D; Locher C; Gornet JM; Thirot-Bidault A; Tougeron D; Taïeb J; Bonnetain F; Aparicio T;
    Cancer; 2011 Apr; 117(7):1422-8. PubMed ID: 21425142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial.
    DeCaprio JA; Mayer RJ; Gonin R; Arbuck SG
    J Clin Oncol; 1991 Dec; 9(12):2128-33. PubMed ID: 1960554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
    Rigg A; Cunningham D; Gore M; Hill M; O'Brien M; Nicolson M; Chang J; Watson M; Norman A; Hill A; Oates J; Moore H; Ross P
    Br J Cancer; 1997; 75(1):101-5. PubMed ID: 9000605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A comparison of two dose regimens in pancreatic cancer.
    Figer A; Sadikov E; Mishaeli M; Koren R; Gal R; Levin I; Klein B
    J Chemother; 2000 Oct; 12(5):442-5. PubMed ID: 11128566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin.
    Kornek GV; Schratter-Sehn A; Marczell A; Depisch D; Karner J; Krauss G; Haider K; Kwasny W; Locker G; Scheithauer W
    Br J Cancer; 2000 Jan; 82(1):98-103. PubMed ID: 10638974
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase III evaluation of octreotide versus chemotherapy with 5-fluorouracil or 5-fluorouracil plus leucovorin in advanced exocrine pancreatic cancer: a North Central Cancer Treatment Group study.
    Burch PA; Block M; Schroeder G; Kugler JW; Sargent DJ; Braich TA; Mailliard JA; Michalak JC; Hatfield AK; Wright K; Kuross SA
    Clin Cancer Res; 2000 Sep; 6(9):3486-92. PubMed ID: 10999733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer.
    Eckel F; Lersch C; Lippl F; Assmann G; Schulte-Frohlinde E
    J Exp Clin Cancer Res; 2000 Sep; 19(3):295-300. PubMed ID: 11144522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tolerance and efficacy of adjuvant chemoradiotherapy with FOLFIRI in adenocarcinoma of stomach and GI junction.
    Des Guetz G; Bouillet T; Wind P; Morere JF
    Gastroenterol Clin Biol; 2008 Oct; 32(10):875-6. PubMed ID: 18487031
    [No Abstract]   [Full Text] [Related]  

  • 32. Advancements in the management of pancreatic cancer: 2013.
    Saif MW
    JOP; 2013 Mar; 14(2):112-8. PubMed ID: 23474549
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
    Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
    Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FOLFIRINOX in locally advanced pancreatic cancer: the starting point for questioning.
    Levy A; Chargari C; Huguet F; Védrine L; Deutsch E
    Pancreas; 2012 Aug; 41(6):973-4. PubMed ID: 22781912
    [No Abstract]   [Full Text] [Related]  

  • 35. 5-Fluorouracil and low-dose leucovorin in metastatic colorectal cancer: a pilot study.
    Fried G; Tsalik M; Stein M; Dale J; Haim N
    Cancer Chemother Pharmacol; 1995; 35(5):437-40. PubMed ID: 7850927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase II evaluation of 5-fluorouracil and low-dose leucovorin in cisplatin-refractory advanced ovarian carcinoma.
    Long HJ; Nelimark RA; Su JQ; Garneau SC; Levitt R; Goldberg RM; Poon MA; Kugler JW
    Gynecol Oncol; 1994 Aug; 54(2):180-3. PubMed ID: 8063243
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complete response of primary bladder adenocarcinoma with the FOLFOX4 regimen.
    Tatli AM; Uysal M; Goksu SS; Gunduz S; Arslan D; Ozdogan M
    Urol Int; 2015; 94(3):363-5. PubMed ID: 24281125
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A FOLFIRI-induced complete tumor response in a patient with FOLFOX-refractory metastatic duodenal adenocarcinoma.
    Catania C; Pelosi G; Fazio N; Biffi R; Spitaleri G; Noberasco C; Zampino MG; Maggioni A; Trifirò G; Toffalorio F; Vigna PD; De Braud F; De Pas T
    Acta Oncol; 2010; 49(1):120-1. PubMed ID: 20100147
    [No Abstract]   [Full Text] [Related]  

  • 39. Pancreatic cancer in 2010: new insights for early intervention and detection.
    Costello E; Neoptolemos JP
    Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):71-3. PubMed ID: 21293504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comments on "Electrochemotherapy with Irreversible Electroporation and FOLFIRINOX Improves Survival in Murine Models of Pancreatic Adenocarcinoma".
    Granata V; Fusco R; Palaia R; Belli A; Petrillo A; Izzo F
    Ann Surg Oncol; 2020 Dec; 27(Suppl 3):954-955. PubMed ID: 33011913
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.